MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

First Posted Date
2020-10-28
Last Posted Date
2023-02-16
Lead Sponsor
University of British Columbia
Target Recruit Count
341
Registration Number
NCT04606563
Locations
🇨🇦

Royal Jubilee Hospital, Nanaimo, British Columbia, Canada

🇨🇦

St Paul's Hospital, Vancouver, British Columbia, Canada

🇨🇦

The Ottawa Hospital, Ottawa, Ontario, Canada

and more 10 locations

The Effects of Losartan on Social Reward

Not Applicable
Conditions
Healthy
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2020-10-27
Last Posted Date
2020-10-27
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
90
Registration Number
NCT04604756
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

The Effects of Losartan on Reward Reinforcement Learning

Not Applicable
Conditions
Healthy
Interventions
Drug: Placebo oral tablet
First Posted Date
2020-10-27
Last Posted Date
2020-10-27
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
60
Registration Number
NCT04604938
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase 2
Active, not recruiting
Conditions
Pancreatic Adenocarcinoma
Stage 0 Pancreatic Cancer AJCC v8
Stage I Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Interventions
Radiation: Radiation Therapy
Procedure: Resection
Procedure: Diagnostic Imaging
Procedure: Biospecimen Collection
First Posted Date
2020-09-07
Last Posted Date
2025-01-03
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
60
Registration Number
NCT04539808
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

First Posted Date
2020-08-07
Last Posted Date
2022-06-16
Lead Sponsor
University of Southern Denmark
Target Recruit Count
10
Registration Number
NCT04504045
Locations
🇩🇰

University of Southern Denmark, Odense, Region Of Southern Denmark, Denmark

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

Phase 2
Terminated
Conditions
Cancer
COVID
Coronavirus Infection
Interventions
First Posted Date
2020-06-25
Last Posted Date
2022-08-09
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
77
Registration Number
NCT04447235
Locations
🇧🇷

Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil

Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention

Early Phase 1
Recruiting
Conditions
Hypertension
Interventions
First Posted Date
2020-05-27
Last Posted Date
2022-10-24
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
90
Registration Number
NCT04403347
Locations
🇨🇳

First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China

🇨🇳

Clinical Medical College&Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China

🇨🇳

Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China

and more 1 locations

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

First Posted Date
2020-04-16
Last Posted Date
2020-11-12
Lead Sponsor
The Camelot Foundation
Target Recruit Count
1800
Registration Number
NCT04349410
Locations
🇺🇸

FHHI-OI-Camelot; QME, Los Angeles, California, United States

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

Phase 3
Withdrawn
Conditions
Covid-19
Interventions
First Posted Date
2020-04-13
Last Posted Date
2020-11-19
Lead Sponsor
London School of Hygiene and Tropical Medicine
Registration Number
NCT04343001
Locations
🇳🇬

University College Hospital, Ibadan, Oyo, Nigeria

🇵🇰

Shifa Tameer-e-Millat University, Rawalpindi, Pakistan

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

Phase 4
Completed
Conditions
SARS-CoV Infection
Interventions
First Posted Date
2020-04-09
Last Posted Date
2021-05-26
Lead Sponsor
Sharp HealthCare
Target Recruit Count
31
Registration Number
NCT04340557
Locations
🇺🇸

Sharp Grossmont Hospital, La Mesa, California, United States

🇺🇸

Sharp Chula Vista Medical Center, San Diego, California, United States

🇺🇸

Sharp Memorial Hospital, San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath